EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT ‐1 study

Kimberly A Gudzune, Adam Stefanski, Dachuang Cao, Donna Mojdami, Fangyu Wang, Nadia Ahmad, Jiat Ling Poon

Diabetes, Obesity and Metabolism · 2025-02 · 27 (2) · 539-550

DOI: 10.1111/dom.16046 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 04.11.2024. Verfasst von Kimberly A Gudzune und 6 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Obesity, Patient Reported Outcome Measures, Quality of Life, Weight Loss. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The SURMOUNT‐1 trial investigated effects of tirzepatide, a glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist, on body weight in participants with obesity or overweight. This analysis evaluated changes in patient‐reported outcomes (PROs) assessing physical function, psychosocial well‐being, and overall health aspects of participants' health‐related quality of life (HRQoL) in SURMOUNT‐1.

Methods

PRO instruments included the Impact of Weight on Quality of Life‐Lite Clinical Trials version (IWQOL‐Lite‐CT), Short Form Survey‐36 version 2 (SF‐36v2) and EQ‐5D‐5L. Scores were analysed by treatment group and by categorical degree of weight reduction group: >0 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityPatient Reported Outcome MeasuresQuality of LifeWeight LossAdultFemaleHumansMaleMiddle AgedAnti-Obesity AgentsDouble-Blind MethodGlucagon-Like Peptide-1 ReceptorOverweightTreatment OutcomeTirzepatide

Stichwörter der Autor:innen

GIPGLP‐1obesity therapypatient‐reported outcomes

Substanzen

Anti-Obesity AgentsGlucagon-Like Peptide-1 ReceptorTirzepatide

Autor:innen und Institutionen

  • Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Gudzune, K. A., Stefanski, A., Cao, D., Mojdami, D., Wang, F., Ahmad, N., & Ling Poon, J. (2025). Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT ‐1 study. Diabetes, Obesity and Metabolism, 27(2), 539-550. https://doi.org/10.1111/dom.16046

Vancouver

Gudzune KA, Stefanski A, Cao D, Mojdami D, Wang F, Ahmad N, et al. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT ‐1 study. Diabetes, Obesity and Metabolism. 2025;27(2):539-550. doi:10.1111/dom.16046

BibTeX
@article{Gudzune2025,
  author = {Gudzune, Kimberly A and Stefanski, Adam and Cao, Dachuang and Mojdami, Donna and Wang, Fangyu and Ahmad, Nadia and Ling Poon, Jiat},
  title = {Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT ‐1 study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {2},
  pages = {539--550},
  doi = {10.1111/dom.16046}
}
Kostenlos starten →